ClinicalTrials.gg
CompletedNCT00413387Updated Aug 3, 2020

Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

A Phase 3 interventional study of beclomethasone dipropionate plus formoterol fumarate combination and budesonide plus formoterol combination in Bronchial Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 13 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-08-03.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
15th of 40
219 · median 67
Started
2004
with 5 others
Phase 3
20 of 40
none open now
Registered
10th of 40
by date
Lead sponsor
12 of 40
Chiesi Farmaceutici S.p.A.

Among the 40 studies testing beclomethasone in Asthma, this one is the 15th largest by enrollment, is one of 6 that started in 2004, is one of 20 in phase 3, and was the 10th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

The aim of this study was to compare the efficacy and tolerability of the fixed combination beclomethasone/formoterol pMDI with that of budesonide/formoterol dry powder via Turbuhaler.

Read the detailed description

Asthma is a chronic disease that is estimated to affect over 25 million people both in the U.S. and in Europe (i.e. approximately 10% of the total population). Pharmacological therapy is used to treat reversible airway obstruction, inflammation and hyper-reactivity. Medications include preventive treatments in forms of antinflammatory/antiallergic agents (i.e. glucocorticosteroids, leukotriene antagonists, cromolyn sodium) and reliever treatments, in forms of bronchodilators (i.e. β-adrenergic agonists, anticholinergics). In patients treated with inhaled glucocorticosteroids whose asthma is not fully controlled, national and international guidelines recommend a stepwise approach. Recent evidence-based clinical trials show that the addition of a LABA to inhaled glucocorticosteroids is more beneficial in terms of asthma control than increasing the dose of corticosteroids alone.

COMPARISONS: CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg+ FORMOTEROL 6 µg) pMDI via HFA-134a compared to SYMBICORT (BUDESONIDE 160 µg + FORMOTEROL 4,5 µg).

03

Conditions studied

  • Bronchial Asthma

Browse trials for

Keywords

  • Asthma
  • Combinations
  • Inhaled therapy
  • Corticosteroids
  • Long acting bronchodilators
  • Beclomethasone
  • Formoterol
  • Budesonide
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of moderate to severe persistent asthma for at least 6 months, according to GINA revised version 2002 guidelines:

    • (FEV1) or peak expiratory flow rate (PEFR) > 50% and \< 80% of the predicted normal;
    • Asthma not adequately controlled with the current therapies, defined as presence of daily asthma symptoms > once a week and night-time asthma symptoms > twice a month, and daily use of short-acting β2-agonists. These findings are to be based on recent medical history and are to be confirmed in the 2-week run-in period.

      • Treatment with inhaled at a daily dose ≤ 1000 μg of BDP or equivalent. The daily dose of inhaled corticosteroids taken at visit 1 will be assessed taking into account the following ratios between the doses of the different steroids: fluticasone propionate : BDP CFC = 1 : 2; budesonide : BDP CFC = 4 : 5; flunisolide : BDP CFC = 1 : 1. The ratios between inhaled steroids are irrespective of the formulations (i.e. spray aerosol or powder) used. When BDP is given in the new extra-fine HFA-134a formulation (as QVAR®, 3M Healthcare), the ratio with BDP CFC is set as 2 : 5. Therefore, the maximum allowed daily dose of inhaled corticosteroids at study entry will be: budesonide 800 μg, fluticasone propionate 500 μg, flunisolide 1000 μg, BDP 1000 mcg, BDP HFA extra-fine 400 μg.
      • Positive response to the reversibility test in the screening visit, defined as an increase of at least 12% (or, alternatively, of 200mL) from baseline value in the measurement of FEV1 30 minutes following 2 puffs (2 x 100 µg) of inhaled salbutamol administered via pMDI. The reversibility test can be avoided in patients having a documented positive response in the previous 6 months.
      • A co-operative attitude and ability to be trained to correctly use the metered dose inhalers and to complete the diary cards.
      • Written obtained.
      • At the end of the 2-week run-in period, the presence of daily asthma symptoms (of at least mild intensity) and nighttime asthma symptom (of at least mild intensity) > once a week, as well as of daily use of relief salbutamol is to be confirmed by reviewing the diary cards for run-in

Exclusion criteria

Exclusion Criteria:

  • Inability to carry out pulmonary function testing;

    • Diagnosis of (COPD) as defined by the National Heart Lung and Blood Institute/World Health Organisation (NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (30);
    • History of near fatal asthma;
    • Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 8 weeks;
    • Three or more courses of oral or hospitalisation due to asthma during the previous 6 months;
    • Patients treated with long-acting β2-agonists, anticholinergics and antihistamines during the previous 2 weeks, with topical or intranasal corticosteroids and leukotriene antagonists during the previous 4 weeks;
    • Patients who have changed their dose of inhaled corticosteroids during the previous 4 weeks, or treatment with inhaled corticosteroids at a daily dose > 1000 μg of BDP or equivalent (except for extra-fine formulations, see inclusion criteria);
    • Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 cigarettes/day;
    • History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe hypertension, cardiac arrhythmias;
    • Diabetes mellitus;
    • Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) during the previous six months;
    • Patients with an abnormal value in the test, defined as > 450 msec in males or > 470 msec in females;
    • Other haemodynamic relevant rhythm disturbances (including atrial flutter or atrial fibrillation with ventricular response, bradycardia (≤ 55 bpm), evidence of atrial-ventricular (AV) block on ECG of more than 1st degree;
    • or unstable concurrent diseases: uncontrolled hyperthyroidism, significant hepatic impairment, poorly controlled pulmonary (tuberculosis, active mycotic infection of the lung), gastrointestinal (e.g. active peptic ulcer), neurological or haematological diseases;
    • Cancer or any chronic diseases with prognosis \< 2 years;
    • Pregnant or lactating females or females at risk of pregnancy, i.e. those not demonstrating adequate (i.e. barrier methods, intrauterine devices, hormonal treatment or sterilization). A pregnancy test is to be carried out in women of a fertile age.
    • History of alcohol or drug abuse;
    • Patients treated with monoamine oxidase inhibitors, tricyclic antidepressants or beta-blockers as regular use;
    • Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients;
    • Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study;
    • Patients who received any new drug within the last 12 weeks;
    • Patients who have been previously enrolled in this study;
    • At the end of the run-in period, patients will not be admitted to the treatment period in the case of an increase of PEFR (L/sec) measured at the clinics at the end of the run-in period > 15% in respect of values measured at the start of the run-in period;
    • Patients with asthma exacerbations during the run-in period will also be excluded from the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    1

    chf1535

    Drug: beclomethasone dipropionate plus formoterol fumarate combination

  • Active comparator
    2

    Symbicort

    Drug: budesonide plus formoterol combination

Interventions

  • Drugbeclomethasone dipropionate plus formoterol fumarate combination

    Drug pages: Beclomethasone · Formoterol

    100mcg beclomethasone diproprionate plus 6 mcg formoterol

  • Drugbudesonide plus formoterol combination

    Drug pages: Budesonide · Formoterol

    200mcg budesonide plus 6 mcg formoterol

06

What researchers measure

Primary outcomes

  1. Morning Peak Expiratory Flow (PEF) daily measured by patients.

    Time frame: morning approximately 8:00

Secondary outcomes

  1. Evening PEF measured by patients daily.

    Time frame: evening approximately 20:00

  2. FEV1 measured by patients daily.

    Time frame: morning and evening

  3. Standard pulmonary function tests measured at clinics at 2, 4, 8 and 12 weeks.

    Time frame: morning before drug intake

  4. Change in FEV1 and PEF from pre-dose to 5, 15, 30 and 60 minutes after study drug intake at week 0 and 12.

    Time frame: morning post drug intake

  5. Symptoms scores measured by patients daily.

    Time frame: morning and evening

  6. symptoms'free days measured by patients daily.

    Time frame: daily

  7. Use of relief salbutamol measured by patients daily.

    Time frame: daily

  8. Frequency of asthma exacerbations evaluated at 2, 4, 8 and 12 weeks.

    Time frame: morning of the visits retrospective assessment

  9. Adverse event and adverse drug reaction daily.

    Time frame: morning of visits retrospective assesment

  10. ECG (with QTc interval)at 0 and 12 weeks.

    Time frame: morning of start and end of treatment visits

  11. Vital signs (heart rate and blood pressure) at 2, 4, 8 and 12 weeks

    Time frame: morning of visits

  12. Use of relief salbutamol.

    Time frame: daily

  13. Frequency of asthma exacerbations.

    Time frame: at visits

07

Study locations

13 sites
  • Ambulance For Paediatric and Pulmonology
    Wien, Austria
  • Nzoz "Medex"Poradnia Alergologiczna
    Bielsko-Biala, Poland
  • Centrum Uslug Medycznych
    Krakow, Poland
  • Centrum Alergologii
    Lodz, Poland
  • Prywatny Gabinet Lekarski
    Lodz, Poland
  • Uniwersytet Medyczny
    Lodz, Poland
  • Nzoz Lekarze Specjalisci
    Wroclaw, Poland
  • Internal Medicine Department, Dniepropetrovsk State Medical Academy. City Clinical Hospital no. 4
    Dniepropetrovsk, Ukraine
  • Institute of Therapy, Ukranian Academy of Medical Science. Pulmonological Departement
    Kharkiv, Ukraine
  • Kharkov Regional Clinical Hospital. Pulmonological and Allergological Department
    Kharkov, Ukraine
  • Institute of Phthisiology and Pulmonology Academy of Medical Science of the Ukraine, Pulmonology Departement
    Kiev, Ukraine
  • Institute of Phthisiology and Pulmonology Academy of Medical Science of the Ukraine. Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases
    Kiev, Ukraine
  • Kiev Medical Academy of Postdiploma Education. Department of Medical Genetics, Clinical Immunology and Allergology
    Kiev, Ukraine
08

References and documents

Publications

  • Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM; Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007 Apr;29(4):682-9. doi: 10.1183/09031936.00095906. Epub 2006 Nov 15. Erratum In: Eur Respir J. 2007 Jun;29(6):1286. Eur Respir J. 2008 Sep;32(3):822. PubMed 17107988 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Aug 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2006
First posted
Dec 19, 2006
Start
Sep 2004
Primary completionActual
Aug 2005
CompletionActual
Oct 2005
Last update
Aug 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00413387
First posted
Dec 19, 2006
Start date
Sep 2004
Primary completion
Aug 2005
Completion
Oct 2005
Last update
Aug 3, 2020

Study contacts

Leonardo M. Fabbri, MD
study chair · Department of Resipiratory Diseases - University of Modena and Reggio Emilia, Modena, Italy
Maurizio A. Vignola, MD
study chair · Institute of Lung Pathophysiology, National Research Council, Palermo, Italy

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Formoterol

Start the discussion